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Introduction
Despite prevention efforts, changes in social policy, and the
advent of effective medications for tobacco dependence, 21% of
the US population currently smokes. Further, upward of 50%
of patients with cancer who were smokers before their diagnosis
continue to smoke, and, even for patients who are able to quit
after their diagnosis, relapse rates are substantial. Tobacco use is
the leading cause of preventable death in the United States, and
continued smoking by patients with cancer can reduce medical
treatment effectiveness and diminish quality of life.
The National Cancer Institute (NCI) cancer centers repre-
sent nodal points to treat tobacco dependence. NCI cancer
centers possess the credibility to help smokers quit, and with the
greater life expectancies forecast for patients with cancer, ad-
dressing smoking at cancer centers has taken on greater impor-
tance. Consequently, in December 2009, the NCI Tobacco
Control Research Branch and the Office of Cancer Survivor-
ship sponsored a 1-day meeting at the National Institutes of
Health on treating tobacco dependence at NCI cancer centers.
This meeting (1) highlighted the importance of treating to-
bacco dependence in the context of cancer care and survivor-
ship, (2) reviewed guidelines for treating tobacco dependence in
the context of cancer care and survivorship, (3) discussed mod-
els for tobacco dependence treatment in the oncologic context,
(4) discussed barriers to the implementation of tobacco depen-
dence treatment in cancer centers, (5) reviewed strategies to
overcome barriers to cessation treatment in cancer settings, and
(6) explored scientific questions related to tobacco dependence
treatment that require further study. Representatives from each
NCI cancer center were invited. The meeting included talks
from the NCI and experts in the field, panel discussions, and
question-and-answer sessions; 65 members from 40 cancer cen-
ters participated. This meeting and overview may help build
capacity for the delivery of tobacco dependence treatment at
NCI cancer centers.
The Problem
Smoking causes 30% of all cancers and 80% of mortality from
head and neck and lung cancer.1-3 Despite policy and scientific
advances, 21% of Americans currently smoke tobacco, upward
of 50% of patients with cancer who smoked before diagnosis
continue to smoke,4 and relapse rates after completion of med-
ical treatment are high.5 There are more than 11.7 million
cancer survivors in the United States, including more than
325,000 adult survivors of childhood/adolescent cancer.6 Up-
ward of 25% of survivors are smokers, including 14% of ado-
lescent cancer survivors.7 Continued smoking by patients and
survivors decreases survival time,8 increases risk for a second
primary cancer,9 reduces medical treatment effectiveness,10,11
and diminishes quality of life after treatment.12,13
Patients with cancer who try to quit smoking typically do so
without formal assistance,14 which yields low success rates.15
Further, the provision of tobacco use treatment is not consid-
ered a “core service” at most NCI cancer centers. The results of
a survey of tobacco use treatment at 58 NCI cancer centers
presented at this meeting for the first time16 showed that, al-
though 60% of cancer centers offered some form of tobacco use
treatment, such services were often confined to one disease sub-
population (eg, lung cancer). Fewer than half of the cancer
centers have designated personnel to offer tobacco use treat-
ment. The availability of tobacco use treatment programs at
cancer centers lags behind that of other models of care (eg,
nutrition).
What’s Needed
An important first step in encouraging cancer centers to address
tobacco dependence is to improve systems for identifying
smokers and referring them to suitable treatment programs. A
uniform measure of smoking status for patients at each visit can
triage patients into effective treatments and assess clinical effects
of continued smoking.17 Including tobacco use as a “vital sign”
on patient medical charts increases the rate of identification of
smokers, rates of treatment, and cessation rates.18,19 Currently,
fewer than half of the 58 cancer centers assess smoking status as
a vital sign,16 yet this procedure is cheap, simple, and effective.
Treatment Guidelines
The US Public Health Service’s Treating Tobacco Use and De-
pendence Clinical Practice Guideline identifies effective treat-
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ments and clinical practices.18 The Guideline underscores that
tobacco dependence is a chronic disease with the need for re-
peated intervention. Interventions as brief as 3 minutes can help
smokers who are ready to quit to utilize effective treatments,
motivate smokers who are not ready to quit to consider treat-
ment, and reduce the risk of relapse among patients who have
recently quit smoking.18 Health care providers are advised to
offer, or facilitate access to, counseling and guideline-recom-
mended medications, which are most effective when combined.
Approved medications include nicotine replacement therapy
(gum, patch, nasal spray, inhaler, lozenge), bupropion, and va-
renicline. The extended use or combination of these medica-
tions does not present a known health risk and may increase
abstinence.18 Because quit-line counseling is available in all
states, has broad reach, and is effective in diverse populations,
clinicians could use this resource as an option.
What’s Needed
Few studies have examined tobacco dependence interventions
for patients with cancer and survivors, especially among adoles-
cents. Many existing trials have used small samples and lacked
biochemical verification.20-22 Only one placebo-controlled trial
of an FDA-approved pharmacotherapy agent has been con-
ducted in patients with cancer, 23and only one large smoking
cessation clinical trial has been conducted with adolescent sur-
vivors24; a second trial with childhood cancer survivors is un-
derway.25 Cancer centers can play a pivotal role in designing
and implementing studies and evaluating methods for dissem-
ination of treatments. Studies could evaluate the use of the full
cancer treatment team (v a single interventionist) or could ex-
amine the optimal timing or duration of tobacco use treatment.
Developing and testing novel behavioral interventions is an
important direction for future research, as are models that in-
clude family members in, or as targets of, the intervention.
Research is needed on how to integrate cessation treatment into
care delivery and how to sustain cessation. The integration of
tobacco use treatments into cancer centers should be guided by
existing guidelines and innovative research.
Treatment Models
The meeting highlighted tobacco dependence treatment pro-
grams at four cancer centers. These programs are summarized in
Table 1 but include the following components:
• Multidisciplinary team for establishing policies and
practices.
• Standardized screening method to identify all smokers at
intake and throughout clinical care.
• Tobacco treatment specialists.
• Intake to guide treatment planning and initiate referrals for
more intensive treatments.
• Counseling to build motivation and coping skills and to
prevent relapse.
• Liaison with oncology care team and education on cessa-
tion medications.
• Staff and patient education about the benefits of cessation
and risks of continued smoking.
• Tobacco cessation research programs that complement and
benefit from clinical service.
• Collection and monitoring of cessation outcomes and qual-
ity of care performance data.
Barriers to Implementation
Despite supportive policies from oncologic organizations,26-28
treatment for tobacco dependence is still not part of standard
cancer care, and only 7% of cancer clinical trials assess smoking
status.29 Barriers to the provision of tobacco dependence treat-
ment in the oncologic context are common across health care
settings (eg, lack of physician time28). Unique barriers and strat-
egies to overcome these barriers30 are reviewed below and in
Table 2.
Patients who smoke might not request help because of their
guilt over smoking,31 fear of being stigmatized,32 or fatalism
about their disease.33 Variability in patient smoking over time
(eg, high quit rates at diagnosis but high relapse rates), hinders
identification. Patients with cancer show high levels of nicotine
dependence,34 possibly requiring combination35 or extended36
treatments. Enforced abstinence as a result of no-smoking pol-
Table 1. Treatment Models at Cancer Centers
Programs
Program Characteristics Massachusetts General Hospital
Memorial Sloan-Kettering
Cancer Center MD Anderson Moffitt
Identification of tobacco
users





Referral by health care provider,





Eligibility Current smokers, recent quitters
(past 12 mo)
Current smokers, recent
quitters (past 30 d)
Current smokers, recent
quitters (past 12 mo)
Current smokers, recent
quitters (past 90 d)
Treatment intensity Level 4 Level 4 Level 4 Level 3
Treatment modality Individual counseling at bedside,
referral to quit line or internal
automated phone reminder system












State tobacco settlement funds Hospital operating budget
NOTE. Level 1: hospital contact for  15 minutes and no discharge support; level 2: hospital contact for  15 minutes and no discharge support; level 3: any hospital contact
and postdischarge support lasting 1 month or less; level 4: any hospital contact and postdischarge support lasting more than 1 month.
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icies can be aversive, reducing future quit attempts. Treatment
options may be limited by medical contraindications, including
trouble swallowing, or by depression; these conditions may re-
quire specialized treatments.37,38
Health care providers may lack awareness of the prognostic
importance of smoking, lack the skill to treat smoking, or worry
about exacerbating patient guilt. Many cancer centers have in-
adequate procedures to identify patients who smoke and triage
Table 2. Strategies to Address Barriers to Implementation of Tobacco Dependence Treatment in Comprehensive Cancer Centers
Barriers/Challenges Strategies
Health care providers
Lack of awareness of tobacco use as a major factor in cancer
control
Provide continuing education programs for oncology professionals within cancer centers.
Limited knowledge about tobacco dependence treatment as a
result of lack of content in professional education, licensure,
and oncology specialty examinations
Ensure that tobacco control is included as part of fellowship/graduate
programs/certification examinations in oncology.
Lack of awareness of Clinical Practice Guideline Conduct and evaluate media campaigns on the importance of tobacco dependence
treatment targeting oncology healthcare professionals.
Lack of awareness of available resources Access existing resources (Table 2).
Limited leadership Identify oncology champions/coordinators to spearhead implementation and evaluation of
tobacco interventions and to lead advocacy efforts.
Recruit leaders across professional groups and consider strategic alliances with tobacco
control groups.
Negative attitudes, including the perception that patients are
not motivated to quit and frustration when smokers relapse;
patient guilt or fatalism
Include information about Motivational Interviewing strategies in educational programs.
Dispel myths and misconceptions about tobacco dependence treatment and provide a
foundation for understanding the power of the addiction.
Lack of time or not a priority Brief interventions are effective and all tobacco users deserve an intervention. A team
approach, using a variety of healthcare professionals, may reduce the time needed by
a single individual. A designated tobacco counselor may be useful for those who need
more intensive treatment. Support and follow-up by telephone quit-line.
Smoking among health care professionals Develop/expand tobacco dependence treatment for all employees.
Institutional/System
Tobacco dependence treatment not a vital aspect of cancer
care in many institutions. Not included as a metric of quality,
care and provider interventions not recognized
Encourage cancer centers to develop a system for identifying smokers and referring to
tobacco dependence treatment.
Encourage cancer centers to make treatment of tobacco dependence part of their core
mission and strategic plan.
Encourage centers to develop outstanding models of care and publication in professional
journals and in communications to the public.
Lack of comprehensive tobacco assessment and dependence
treatment
Include ongoing assessment of tobacco use of all patients on all medical records. Indicate
delivery of advice to quit, the provision of counseling, pharmacotherapy, and methods
for monitoring and addressing relapse.
Assess exposure to secondhand smoke. As appropriate, include assessment and
support for family members.
Limited incentive for intervention Hold a leadership summit to develop strategies to integrate tobacco dependence
treatment as part of quality cancer care and public policy.
Develop a quality improvement mechanism for ongoing assessment and feedback on
implementation of tobacco dependence within the cancer center.
Limited patient and family awareness of the importance of
quitting tobacco use and decreasing exposure to second-
hand smoke
Provide patient-friendly materials about quitting, including information about the Quit-line,
the role of medications and the importance of family support.
Create materials specific to the cancer center.
Increase patient demand through a media campaign focusing on special resources at the
cancer center.
Limited insurance coverage for intervention Develop a system to clearly identify the types of coverage by various insurers.
Lack of awareness of existing coverage in different public and
private plans
Engage oncology leadership in collaborative efforts to promote coverage by insurers.
Limited space and resources Provide data about the effectiveness of tobacco dependence treatment to cancer center
leadership to support need for space allocation and resources.
Support for in-house tobacco treatment specialists/coordinators may improve quality
care.
Policy
Lack of comprehensive smoke-free campus policies Develop policies and strategies to ensure that Cancer Centers are smoke-free.
Limited implementation of existing tobacco control policies in
guiding oncology practice
Encourage professional organizations to develop and evaluate the implementation of
policies.
Lack of recognition of quality programs Changes in the Joint Commission Quality Indicator for tobacco dependence treatment to
increase awareness of outstanding organizational efforts.
Highlight model programs on NCI website.
Research
Limited research in tobacco dependence treatment and
patients with cancer
Few oncology researchers are experts in tobacco control and
vice versa
Provide opportunities within and between cancer centers for discussions and
collaborations between oncology and tobacco control researchers.
Lack of inclusion of tobacco use in cancer clinical trials Encourage cancer centers to make data collection about tobacco use essential to any
human cancer trial.
Morgan et al
180 JOURNAL OF ONCOLOGY PRACTICE • VOL. 7, ISSUE 3 Copyright © 2011 by American Society of Clinical Oncology
them to treatments. The Joint Commission may include docu-
mentation of tobacco use status, delivery of treatments, and
provision of follow-up care as a quality indicator.39 The transi-
tion to electronic medical records may incorporate tobacco use
as a vital sign19 and use electronic reminders to ensure compli-
ance with repeated assessments and treatment referral.20
Given practical constraints, it is unreasonable to expect that
health care providers can provide comprehensive tobacco de-
pendence treatment. Nevertheless, tobacco dependence treat-
ment must become a greater priority at cancer centers. The
burden of treatment can extend beyond the oncologist to in-
clude nurses, pharmacists, psychologists, and social workers.
Referral to in-house or community-based treatments or quit
lines is essential. Resources are available to assist with the inte-
gration of tobacco use assessment and treatment into cancer
centers (Table 3).
Summary
The convergence of motivated and talented clinicians, en-
hanced technology, treatment guidelines, models of care, and
evolving hospital accreditation standards may accelerate prog-
ress in treating tobacco dependence at NCI cancer centers.
With a constituency of close to 12 million Americans living
with cancer,6 cancer centers have the opportunity to be the
exemplars in tobacco dependence research and treatment. Can-
cer centers, with their talented and committed faculty, are op-
timally positioned to perform cutting-edge research, inform the
field of tobacco dependence treatment, and meet the call to
action from the NCI40 and ASCO.27 The Treating Tobacco
Dependence at Cancer Centers meeting served as a springboard
to develop or refine center approaches to treating tobacco de-
pendence and expanded and energized the community of sci-
entists devoted to this endeavor. Priorities to enhance the
quality of care for tobacco dependence at cancer centers include
(1) developing consensus regarding the assessment of smoking
status, (2) refining electronic medical records and clinical trials
to ensure the identification and referral of smokers, (3) evalu-
ating novel treatments for cancer patients, and (4) evaluating
methods to overcome barriers to providing smoking cessation
treatment. The academic resources at cancer centers and the
motivation and commitment of cancer center representatives
suggest that the future will see cancer centers leading the way in
treating tobacco dependence and contributing substantially to
further reductions in tobacco-related morbidity and mortality.
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Table 3. Selected Resources for Patients, Health Care Professionals, and Institutions to Support Education and Treatment of
Tobacco Dependence in Cancer Centers
Resource Type Location
Agency for Healthcare Research and Quality’s Clinical Practice Guideline http://www.ahrq.gov/path/tobacco.htm
Telephone quit line: online smoking cessation counseling 1-800 Quit-Now; http://www.naquitline.org/?pageAboutNAQC
National Cancer Institute’s Smokefree.gov: online quitting assistance http://www.smokefree.gov/
Center for Tobacco Research and Intervention at the University of Wisconsin:
materials for health care providers, researchers, smokers, insurers, employers,
and advocates
http://www.ctri.wisc.edu/
Association for the Treatment of Tobacco Use and Dependence: lists of tobacco
dependence treatment training programs
http://www.attud.org/findprog.php
National Alliance for Tobacco Cessation: online smoking cessation program http://www.becomeanex.org/
Smoking Cessation Leadership Center at University of California, San Francisco http://smokingcessationleadership.ucsf.edu/
Destination Tobacco Free: A practical tool for hospitals and health systems
provides detailed support for implementing a tobacco-free policy
http://smokingcessationleadership.ucsf.edu/HospitalSF.htm
Tobacco-Free Nurses: resources for nurses including a library of publications www.tobaccofreenurses.org
American Cancer Society: materials on tobacco for health care professionals and
patients, including the Quit for Life telephone-based counseling program offered
through Free and Clear
http://www.cancer.org/docroot/PED/ped_10.asp
Resources for patients with mental health and substance abuse disorders http://smokingcessationleadership.ucsf.edu/BehavioralHealth.htm
http://smokingcessationleadership.ucsf.edu/Downloads/MH/Toolkit/
NASMHPDtoolkt.pdf
Society for Nicotine and Tobacco Research: provides links and information to
latest research about tobacco
http://www.srnt.org
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